128.54

0.71% 0.91

Abbott Laboratories (ABT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Abbott Laboratories stock is traded at $128.54, with a volume of 6.80M. It is up +0.71% in the last 24 hours and down -4.20% over the past month. Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Previous Close:

$127.63

Open:

$127.86

24h Volume:

6.80M

Relative Volume:

1.07

Market Cap:

$223.72B

Revenue:

$43.84B

Net Income/Loss:

$13.94B

P/E Ratio:

16.07

EPS:

7.9979

Net Cash Flow:

$6.78B

1W Performance:

-3.04%

1M Performance:

-4.20%

6M Performance:

-1.86%

1Y Performance:

+9.03%

1-Day Range:

$127.21

$129.26

1-Week Range:

$125.74

$133.34

52-Week Range:

$110.86

$140.84

Abbott Laboratories Stock (ABT) Company Profile

Name

Abbott Laboratories

Sector

Healthcare (1134)

Industry

Medical Devices (145)

Phone

(224) 667-6100

Address

100 ABBOTT PARK ROAD, ABBOTT PARK, IL

Employee

114,000

Twitter

@AbbottNews

Next Earnings Date

2025-10-15

Latest SEC Filings

ABT's Discussions on Twitter

Compare ABT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABT Abbott Laboratories	128.54	222.13B	43.84B	13.94B	6.78B	7.9979
BSX Boston Scientific Corp	99.24	144.89B	18.49B	2.50B	3.49B	1.6801
SYK Stryker Corp	374.42	141.17B	23.82B	2.92B	4.02B	7.5574
MDT Medtronic Plc	95.78	121.91B	34.20B	4.69B	5.30B	3.6218
EW Edwards Lifesciences Corp	74.64	42.65B	5.69B	1.41B	577.90M	6.9828

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-25	Initiated	The Benchmark Company	Buy
Jul-18-25	Upgrade	Jefferies	Hold → Buy
Jun-16-25	Initiated	Leerink Partners	Market Perform
Oct-08-24	Initiated	Oppenheimer	Outperform
Sep-19-24	Initiated	Piper Sandler	Overweight
Jul-30-24	Downgrade	Edward Jones	Buy → Hold
May-30-24	Initiated	Goldman	Buy
Jul-21-23	Upgrade	Wolfe Research	Underperform → Peer Perform
May-30-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-20-23	Reiterated	Barclays	Overweight
Apr-20-23	Reiterated	Bernstein	Outperform
Apr-20-23	Reiterated	JP Morgan	Overweight
Apr-20-23	Reiterated	Raymond James	Outperform
Apr-20-23	Reiterated	UBS	Buy
Apr-20-23	Reiterated	Wolfe Research	Underperform
Mar-29-23	Initiated	UBS	Buy
Oct-26-22	Initiated	Mizuho	Neutral
Oct-18-22	Initiated	Barclays	Overweight
Oct-12-22	Initiated	Jefferies	Hold
Jul-06-22	Initiated	Wolfe Research	Underperform
Mar-02-22	Resumed	BofA Securities	Buy
Jan-27-22	Reiterated	Credit Suisse	Outperform
Jan-27-22	Reiterated	Morgan Stanley	Overweight
Jan-27-22	Reiterated	Raymond James	Outperform
Jan-27-22	Reiterated	UBS	Buy
Dec-10-21	Initiated	RBC Capital Mkts	Outperform
Oct-27-21	Upgrade	Atlantic Equities	Neutral → Overweight
Oct-14-21	Initiated	Redburn	Neutral
May-25-21	Initiated	Barclays	Overweight
Apr-15-21	Initiated	Atlantic Equities	Neutral
Jan-28-21	Upgrade	BTIG Research	Neutral → Buy
Sep-11-20	Initiated	Wolfe Research	Outperform
Jun-01-20	Downgrade	Goldman	Neutral → Sell
Mar-05-20	Initiated	Citigroup	Buy
Feb-13-20	Initiated	Goldman	Neutral
Feb-06-20	Resumed	BTIG Research	Neutral
Jan-02-20	Downgrade	Guggenheim	Buy → Neutral
Jun-13-19	Reiterated	BofA/Merrill	Buy
Feb-07-19	Reiterated	BofA/Merrill	Buy
Jan-02-19	Downgrade	Citigroup	Neutral → Sell
Nov-30-18	Upgrade	Goldman	Neutral → Buy
Oct-16-18	Initiated	Barclays	Overweight
Jun-27-18	Initiated	Bernstein	Outperform
Jan-30-18	Reiterated	Citigroup	Neutral
Jan-25-18	Reiterated	Stifel	Buy
Jan-25-18	Upgrade	William Blair	Mkt Perform → Outperform
Jan-03-18	Initiated	Evercore ISI	Outperform
Jan-02-18	Upgrade	JP Morgan	Neutral → Overweight
Jan-02-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-19-17	Reiterated	RBC Capital Mkts	Outperform
Oct-19-17	Reiterated	Stifel	Buy

View All

Abbott Laboratories Stock (ABT) Latest News

Oct 18, 2025

How Abbott Laboratories stock reacts to job market data2025 Market Outlook & Verified High Yield Trade Plans - Trung tâm Dự báo KTTV quốc gia

Oct 18, 2025

What makes Abbott Laboratories stock attractive to growth fundsPortfolio Profit Report & Safe Entry Momentum Tips - Trung tâm Dự báo KTTV quốc gia

Oct 18, 2025

Abbott: GLP-1 BeneficiaryDividend Raise May Be Coming (NYSE:ABT) - Seeking Alpha

Oct 18, 2025

How Abbott Laboratories stock compares to growth peersMarket Trend Review & Weekly High Return Stock Opportunities - Trung tâm Dự báo KTTV quốc gia

Oct 18, 2025

Is Abbott Laboratories (ABL) stock cheap by valuation metricsForecast Cut & Free Reliable Trade Execution Plans - Trung tâm Dự báo KTTV quốc gia

Oct 18, 2025

Oct 17, 2025

How Abbott Laboratories stock responds to policy changes2025 Earnings Impact & AI Based Buy/Sell Signal Reports - nchmf.gov.vn

Oct 17, 2025

Is Abbott Laboratories stock a good choice for value investors2025 Market Overview & Community Trade Idea Sharing - nchmf.gov.vn

Oct 17, 2025

Q&A: What cardiologists know and don’t know about pulsed field ablation - Cardiovascular Business

Oct 17, 2025

Abbott Laboratories Stock (ABT) Opinions on Q3 2025 Earnings Report - Quiver Quantitative

Oct 17, 2025

Can Abbott (ABT) Balance Medical Devices Growth Against Diagnostics Challenges in 2025? - simplywall.st

Oct 17, 2025

Abbott Laboratories price pressured by negative technical patternForecast today17-10-2025 - Economies.com

Oct 17, 2025